William Blair analyst Sami Corwin has maintained their bullish stance on PTCT stock, giving a Buy rating on March 14.
Sami Corwin has given his Buy rating due to a combination of factors that highlight the promising potential of PTC Therapeutics’ sepiapterin treatment for PKU. The recent data from the Phase III APHENITY extension trial indicates that a significant majority of patients were able to liberalize their diets, with many achieving or exceeding the recommended daily allowance of protein while maintaining safe blood Phe levels. This suggests that sepiapterin offers a more flexible and effective dietary management option compared to existing treatments.
Furthermore, the trial results underscore sepiapterin’s well-tolerated safety profile, with minimal discontinuations due to adverse events. The genetic analysis also points to a higher-than-expected proportion of patients with classical PKU benefiting from the treatment. These findings support the view that sepiapterin could play a crucial role in advancing PKU care, potentially leading to favorable regulatory outcomes and commercial success, thus justifying the Buy rating.
Corwin covers the Healthcare sector, focusing on stocks such as Solid Biosciences, Sarepta Therapeutics, and PTC Therapeutics. According to TipRanks, Corwin has an average return of 4.6% and a 39.63% success rate on recommended stocks.
In another report released on March 14, J.P. Morgan also maintained a Buy rating on the stock with a $72.00 price target.